Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Laxmi Organic Industries Limited (LXCHEM.NS)
Mumbai, IN
Laxmi Organic Industries Limited is an Indian-based manufacturer focused on specialty chemicals, supplying both acetyl and specialty intermediates. Its range of acetyl intermediates includes compounds such as ethyl acetate, acetaldehyde, and fuel-grade ethanol, along with various proprietary solvents. The company's specialty intermediates category encompasses ketene and diketene derivatives, specifically esters, acetic anhydride, amides, arylides, and other related chemical substances. These versatile products are extensively utilized across numerous industries, including pharmaceuticals, agrochemicals, dyes and pigments, inks and paints, coatings, printing, packaging, flavour and fragrance, adhesives, electronics, automotive, and a wide array of other industrial applications. Beyond its domestic market, the company has a global reach, exporting its goods to approximately 43 countries. Laxmi Organic Industries Limited was founded in 1989 and is headquartered in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.71% | -1.31% | +10.16% | +18.21% | -15.62% | -8.74% | -20.80% | -39.88% | -33.90% | -6.11% | -6.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 2 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-4.7% Q1'26: +3.6% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-29.7% Q1'26: -2.5% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+4.3% Q1'26: -25.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+3.3% Q1'26: +4.7% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+3.5% Q1'26: +3.8% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-0.5% ★ Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×3.17× Q1'26: 2.53× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
30.80B
est: 30.84B (-0.1%)
|
27.97B
est: 27.97B (+0.0%)
|
28.34B
est: 28.54B (-0.7%)
|
29.85B
est: 31.95B (-6.6%)
|
28.52B
23.01B – 34.04B
-10.7% YoY
|
31.91B
26.76B – 37.06B
+11.9% YoY
|
36.99B
28.84B – 45.13B
+15.9% YoY
|
| EBITDA |
3.80B
est: 3.30B (+15.0%)
|
2.59B
est: 3.00B (-13.5%)
|
2.86B
est: 2.69B (+6.5%)
|
2.80B
est: 3.01B (-7.1%)
|
2.69B
2.17B – 3.21B
-10.7% YoY
|
3.01B
2.52B – 3.49B
+11.9% YoY
|
3.48B
2.72B – 4.25B
+15.9% YoY
|
| EBIT |
3.32B
est: 2.40B (+38.4%)
|
1.87B
est: 2.17B (-14.1%)
|
1.77B
est: 1.85B (-4.2%)
|
1.56B
est: 2.07B (-24.7%)
|
1.84B
1.49B – 2.20B
-10.7% YoY
|
2.06B
1.73B – 2.40B
+11.9% YoY
|
2.39B
1.87B – 2.92B
+15.9% YoY
|
| Net Income |
2.57B
est: 2.71B (-5.2%)
|
1.25B
est: 1.81B (-31.3%)
|
1.21B
est: 1.17B (+3.4%)
|
1.14B
est: 1.80B (-37.1%)
|
1.18B
886.18M – 1.48B
-34.4% YoY
|
1.27B
935.02M – 1.84B
+7.3% YoY
|
1.80B
1.20B – 2.49B
+41.6% YoY
|
| SGA |
1.26B
est: 1.34B (-6.1%)
|
1.19B
est: 1.22B (-2.2%)
|
1.51B
est: 1.78B (-14.7%)
|
1.50B
est: 1.99B (-24.5%)
|
1.77B
1.43B – 2.12B
-10.7% YoY
|
1.98B
1.66B – 2.31B
+11.9% YoY
|
2.30B
1.79B – 2.81B
+15.9% YoY
|
| EPS |
9.76
est: 9.73 (+0.3%)
|
4.70
est: 6.50 (-27.7%)
|
4.46
est: 4.27 (+4.4%)
|
4.10
est: 6.50 (-36.9%)
|
4.27
3.19 – 5.34
-34.4% YoY
|
5.00
3.37 – 6.63
+17.2% YoY
|
6.65
4.33 – 8.97
+33.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree India Earnings Fund EPI | 0.02% | 422.8K | 0.84% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 43.6K | 0.65% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ravi Vasudeo Goenka | Executive Chairman | 87M | male |
| Rajan Venkatesh | MD, Chief Executive Officer & Director | 66M | — |
| Harshvardhan Goenka | Interim CFO, President & Executive Director | 23M | male |
| Prateek Singh | Chief Human Resources Officer | — | male |
| Salil Mukundan | Chief Technology Officer | — | male |
| Susheel Mittal | Chief Supply Chain Officer | — | male |
| Uday Vaishampayan | Executive Vice President Of EHS | — | male |
| Aniket Bavchand Hirpara | Company Secretary, Compliance Officer & Senior Vice President of Legal and Secretarial | — | male |
| Virag Shah | President of Specialties BU | — | male |
| Jitendra Agarwal | President of Essentials BU | — | male |
| Mahadeo Karnik | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LXCHEM.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
